| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794527 | Ophthalmology Retina | 2018 | 11 Pages |
Abstract
After 12 months of treatment with IAI, treatment-naïve patients showed substantial functional benefit, whereas previously treated patients maintained their VA. With regular IAI treatment, it seems that similar results as those in pivotal IAI studies can be achieved in routine clinical practice.
Keywords
SPCCrtnAMDPRNIAITEAEfluorescein angiographyAuraintravitreal aflibercept injectionTREXVisual acuitysummary of product characteristicsneovascular age-related macular degenerationcentral retinal thicknesspro re natatreatment-emergent adverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)WaveViewCOMPASS
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Carsten MD, Nicole MD, Thomas MD, Zoran MD, Claudia MD, Kristian T. MD, Miriam Kahl, Helmut MD, Harald MD, Ulrich MD, Peter MD, Joachim MD,